🇺🇸

US SEC Filing Intelligence

· daily

Nasdaq 100 Stocks SEC Filings — April 10, 2026

Across 18 NASDAQ-100 related filings from April 10, 2026, proxy season dominates with 7 filings (DEF 14A/DEFA14A) signaling upcoming AGMs in May 2026 for director elections, equity incentive plans, and auditor ratifications, reflecting governance focus amid equity comp expansions. Financial results show mixed trends: Simulations Plus delivered strong Q1 FY2026 revenue +8.3% YoY and net income +47.5% YoY, while Canadian Solar's FY2025 revenue fell 6.6% YoY but gross margins expanded +160 bps to 18.3%; contrasts sharply with Cumulus Media's FY2025 revenue -10.3% YoY and Chapter 11 filing. Biotech and AI sectors shine with clinical progress (MetaVia dosing milestone), product expansions (AITX RAD to 30 units), and leadership retention/incentives (Alphabet exec PSUs/GSUs worth $34M-$48M each, Immunic CEO bonus). No widespread insider selling noted, but option grants and equity awards indicate management alignment. Capital allocation leans toward equity incentives over dividends/buybacks, with operational cash improvements in Simulations Plus (+142% YoY) and Canadian Solar (less cash burn). Portfolio-level, 3/5 financial reports show profitability gains despite revenue softness, but media sector distress (Cumulus EBITDA -37.1% YoY) warrants caution; catalysts cluster in late May AGMs.

11 high priority 7 medium 18 total filings
· daily

S&P 500 Financials Sector SEC Filings — April 10, 2026

Across the 50 filings, a dominant theme is the ramp-up to proxy season with 15+ AGMs scheduled in May 2026 (e.g., Plains GP/PAA May 20, Riley May 12, Vontier June 4), featuring routine director elections, auditor ratifications, and advisory pay votes passing overwhelmingly where reported. SPAC and M&A activity surges positively, including Constellation/US Elemental $500M combo (H2 2026 close), Willow Lane/Boost Run EGM Apr 30, and Abra/New Providence crypto merger webinar highlighting Bitcoin at $72k outperforming gold. Period-over-period trends show mixed financial health: stark declines like Li Auto revenues -22.3% YoY and net income -86%, Qudian revenues -81.1% YoY but net income +673% on non-op gains, offset by positives like Riley equity +22% YoY, debt -32%, dividend +5%, and $100M buyback. Capital allocation leans shareholder-friendly with News Corp $1B repurchase, Hecla full $263M note redemption for unencumbered balance sheet, and Onfolio share increase to 300M enabling flexibility. Sentiment skews neutral/positive (70%+), but outliers flag China exposure risks (Li Auto, Qudian) and cost pressures (Retractable workforce cut). Portfolio-level, 4/7 quantifiable trends indicate revenue weakness in non-US ops (-20-80% YoY) but balance sheet strengthening via debt paydowns/deals; implications favor monitoring May catalysts for governance stability and H2 M&A unlocks in SPACs/energy.

28 high priority 22 medium 50 total filings
· daily

S&P 500 Consumer Staples Sector SEC Filings — April 10, 2026

Across 50 filings from the USA S&P 500 Consumer Staples intelligence stream (despite diverse inclusions like energy, mining, and SPACs), a dominant theme is proxy season preparation with 20+ DEF 14A/DEFA14A filings highlighting robust 2025 performance, including average revenue growth of ~35% YoY where reported (e.g., Hecla +53%, ClearSign +44%, Garrett + strong sales), deleveraging (Hecla debt -50% YoY), and capital returns via buybacks/dividends (Garrett $208M repurchases, Welltower dividend +10.4%). Period-over-period trends show NOI/margin expansion in outperformers (Welltower 14.1% YoY NOI, Garrett 14.2% Adj EBIT margin) but pockets of weakness like Angel Studios Q1 2026 EBITDA loss $(4-6)M despite $105-109M revenue guidance. Critical developments include SPAC mergers (Constellation $500M equity value, H2 2026 close), spin-offs (Honeywell Aerospace Q3 2026), and auditor changes, signaling portfolio-level focus on growth investments and shareholder value amid positive sentiment in 60% of high-materiality filings. Market implications point to near-term catalysts from May 2026 AGMs, with relative outperformance in capital allocators vs. ongoing loss-makers like TV Channels (losses narrowing -5% YoY but deepening deficit).

26 high priority 24 medium 50 total filings
· daily

S&P 500 Industrials Sector SEC Filings — April 10, 2026

Across 50 filings from S&P 500 Industrials and adjacent sectors, proxy statements dominate (e.g., DEF 14A/DEFA14A for Honeywell, Hecla, Garrett Motion, DuPont), highlighting strong 2025 recaps with revenue growth in outliers like Hecla Mining (+53% YoY to $1.4B) and Garrett Motion ($3.58B sales), alongside capital returns via buybacks ($208M Garrett, $1.2B Royalty Pharma) and deleveraging (Hecla debt -50% YoY to $276M). Period-over-period trends show mixed results: bullish growth in production (Hecla silver +5% YoY, gold +6%) and profitability (Garrett Adj EBIT margin 14.2%), but bearish shifts like Magic Empire revenue -9.8% YoY, JIADE costs tripling to net loss, and Angel Studios Q1 EBITDA loss despite $105-109M revenue prelims. Key developments include Honeywell's separations into three entities (Solstice spun Oct 2025, Aerospace Q3 2026), Hecla full debt redemption unlocking growth capex, and Spire Global's $70M raise for space tech expansion. Portfolio-level patterns reveal proxy-driven governance refreshes (new directors at Honeywell, Remitly), capital flexibility emphasis, and upcoming May 2026 AGMs as catalysts, signaling sector resilience amid macro challenges but with pockets of margin pressure and cash burn.

31 high priority 19 medium 50 total filings
· daily

S&P 500 Energy Sector SEC Filings — April 10, 2026

Across the four filings in the S&P 500 Energy intelligence stream, neutral sentiment dominates with Occidental Petroleum's preliminary Q1 2026 realized prices showing oil at 97% of WTI ($69.91/Bbl) but NGL and gas significantly below indices (26% of WTI/NYMEX), signaling pricing weakness outside crude. Devon Energy's pro forma merger financials with Coterra highlight ongoing consolidation in E&P, prepared under Reg S-X with combined 2025 balance sheet and reserves data. Robert Half's DEF 14A reveals sharp 2025 declines (revenues -7% YoY, net income -47% YoY, EPS -45% YoY) amid staffing uncertainty, contrasting energy stability despite its non-core inclusion. Cooke Wealth Management's 13F shows unchanged Q/Q holdings including Chevron ($427k, 2,064 shares), indicating steady institutional conviction in energy majors. No broad insider activity or capital allocation shifts noted, but merger progress and low NGL/gas realizations point to selective opportunities in oil-focused producers amid subdued gas pricing. Sector implications include M&A momentum but pricing pressures capping upside without index recovery.

1 high priority 3 medium 4 total filings
· daily

US Material Events SEC 8-K Filings — April 10, 2026

Across 50 US SEC 8-K filings dated April 10, 2026, overarching themes include a surge in equity capital raises totaling over $520M (e.g., SPAC IPOs at $200M and $150M, private placements up to $75M ATM), numerous executive and board changes (26 instances, predominantly neutral retirements or appointments with no disagreements cited), debt optimizations and credit expansions enhancing liquidity (e.g., Hecla’s $263M note redemption, CoreCivic’s revolver increase to $400M), and SPAC developments amid mixed M&A outcomes like Dynamix’s $50M termination payout. No explicit period-over-period declines reported across filings; instead, positive forward-looking catalysts dominate, such as Phase 3 funding, manufacturing expansions, and acquisition financings, signaling portfolio-level deleveraging and growth capital access. High materiality events (8-10/10) cluster in financings and debt events, implying bullish liquidity trends for small/mid-caps in biotech, mining, and SPACs versus neutral governance churn in larger caps. Sector implications favor opportunistic plays in space/tech (Spire, Everspin) and mining (Hecla), while exec transitions warrant monitoring for continuity risks. Aggregate capital allocation leans shareholder-friendly via buyback-enabling balance sheets and growth investments, with no dividend cuts or insider sales noted.

50 high priority 50 total filings
· daily

Dow Jones 30 Stocks SEC Filings — April 10, 2026

Across 50 SEC filings from Dow Jones 30-related and associated entities, proxy season dominates with over 25 DEF 14A/DEFA14A filings announcing AGMs in May-June 2026, focusing on director elections, auditor ratifications, and say-on-pay votes, signaling routine governance but potential for activist interventions. Positive themes include M&A accretion (McCormick/Unilever Foods expected EPS uplift Year 1, $600M synergies), corporate restructurings (Honeywell spin-offs completed SOLS Oct 2025, Aerospace Q3 2026), and financings (Annovis $10M for Alzheimer's Phase 3, Spire $70M for space growth). Period-over-period trends show mixed results: VeriSign revenue +6.4% YoY to $1.66B, Voya adj EPS +22% with $775M excess capital, but declines in Magic Empire revenue -9.8% YoY, FRP Q4 net income -77% YoY, EvoAir Q2 revenue -5% YoY. Capital allocation leans toward returns (Voya $374M shareholder returns) and expansions (CoreCivic revolver +$100M to $400M). No widespread insider trading patterns, but strong AGM vote approvals (Biglari 95% turnout, Onfolio 89-97% approvals) indicate shareholder alignment. Key implications: Watch May catalysts for governance shifts, favor growth stories like Voya/VeriSign amid small-cap weakness.

28 high priority 22 medium 50 total filings
· daily

US SEC Filings Daily Market Digest — April 10, 2026

Across 50 SEC filings dated April 10, 2026, proxy season dominates with 15+ DEF 14A/DEFA14A filings signaling upcoming AGMs in May (e.g., Plains, Riley, Honeywell), highlighting governance stability but limited financial insights. Period-over-period trends reveal stark contrasts: Li Auto's revenues plunged 22.3% YoY and net income 86.0% YoY, Qudian's revenues cratered 81.1% YoY despite 673% net income surge from non-op gains, while Riley Exploration grew equity 22% and cut debt 32% post-acquisitions. SPAC and M&A activity surges with 5 deals (Constellation $500M equity value, Willow Lane S-4 effective, McCormick-Unilever $600M synergies), alongside deleveraging (Hecla full $263M note redemption) and financings ($10M Annovis, $93M New ERA). Capital allocation leans shareholder-friendly with buybacks (News Corp $1B, Riley $100M), dividend hikes (Riley +5%), and redemptions, but risks emerge in cost cuts (Retractable workforce reduction, Snail 25% fee cut). Sector patterns show energy/mining resilience via debt reduction and M&A, while Chinese firms face revenue headwinds amid robust liquidity. Overall, actionable alpha lies in SPAC catalysts (Apr-May closings), deleveraging plays, and proxy-driven governance watches, with mixed sentiment (18 positive, 24 neutral, 4 negative, 4 mixed).

27 high priority 23 medium 50 total filings
· daily

S&P 500 Consumer Discretionary Sector SEC Filings — April 10, 2026

Across 50 filings in the USA S&P 500 Consumer Discretionary stream (broadly including retail, auto, restaurants), proxy statements dominate (over 20 filings) signaling peak AGM season with neutral sentiment, while 13F-HR reports (9 filings) reveal neutral institutional positioning in ETFs and tech giants like Alphabet, Amazon, NVIDIA. Period-over-period trends show mixed results: revenue declines averaging -4% YoY in reporting firms (FGI -1%, Brownie's -8%), but strong growth in outliers like TWFG (+22% revenue, +44% NI) and Voya (>22% adj EPS growth); NOI slight upticks in real estate plays like FRP (+2% total NOI) contrast multifamily declines. M&A/SPAC activity bullish with advancements like Willow Lane EGM on April 30 and Boost Run Nasdaq listing imminent, alongside positive capital raises (e.g., XPLR $232M loan). Forward-looking catalysts cluster in late April-May 2026 AGMs, with limited insider data but board refreshers indicating governance focus. Overall, neutral-to-mixed sentiment (materiality avg 5-6/10) suggests stable consumer disc positioning amid economic uncertainty, favoring SPAC de-SPACs and growth outliers for alpha.

21 high priority 29 medium 50 total filings
· daily

S&P 500 Healthcare Sector SEC Filings — April 10, 2026

Across 50 filings in the USA S&P 500 Healthcare stream (though many span adjacent sectors like financials, energy, and tech), dominant themes include proxy season ramp-up with 20+ DEF 14A/DEFA14A filings highlighting 2025 performance, institutional 13F snapshots showing ETF-heavy portfolios (e.g., S&P 500, Nasdaq premium income), and biotech/pharma revenue pressures offset by clinical wins. Period-over-period trends reveal sharp declines in healthcare biotechs (Akston -99% YoY revenue, Scilex -47% YoY to $30.3M with net loss widening to $374M from $72.8M), contrasted by financial outperformers like Voya (+22% adj EPS, $1B+ earnings) and Velocity (+53.5% net income YoY to $105M). Critical developments: Scilex SP-102 Phase 3 success (p=0.003 primary endpoint), Humana board refresh with healthcare expert, iSpecimen 85% shipping efficiency gain; M&A/capital activity active (Beneficient $8.75M NAV deal, New Era $93.4M offering). Portfolio-level: Margin deterioration in biotechs/pharma (e.g., Octave Insurance Distribution loss to $23.1M from $8.2M), but capital returns strong (News Corp $1B buyback, FREIT $0.10 Q2 dividend); implications favor monitoring May 2026 AGMs for comp/governance votes amid volatility from offerings (Akston IPO, Conexeu direct list).

21 high priority 29 medium 50 total filings
· daily

US Executive Compensation Proxy SEC Filings — April 10, 2026

Across 50 DEF 14A proxy statements filed around April 10, 2026, a dominant theme is robust 2025 performance in energy, mining, and financial sectors, with 12/50 filings highlighting YoY revenue growth averaging +30% (e.g., Hecla +53%, TWFG +22%), deleveraging (Riley debt -32%, Hecla -50%), and enhanced shareholder returns via dividends (Welltower +10.4%, Riley +5%) and buybacks (Garrett $208M reducing shares >40%, Royalty Pharma $1.2B). Neutral sentiment prevails in 70% of filings focused on routine governance (director elections, auditor ratifications, say-on-pay), but positive outliers like Voya (+22% adjusted EPS, $374M returns) and Seacoast (NIM +10% YoY, 9% loan growth) signal sector strength amid M&A activity (Riley Silverback acquisition +50% locations, Hope Bancorp Territorial entry). Mixed cases (Masco sales/margins down, Octave premiums -6%) reflect macro challenges, with no widespread insider selling but board refreshments (e.g., Honeywell spins, Bausch new directors) indicating strategic shifts. Portfolio-level trends show margin expansion in high-performers (Garrett 14.2% Adj EBIT) vs compression in industrials, setting up May-June 2026 meetings as key catalysts for comp approvals and plan amendments. Implications favor overweighting energy/financials with strong capital returns, monitoring spin-offs like Honeywell Aerospace (Q3 2026), and avoiding underperformers with quorum issues (Vinebrook). Overall, bullish undertone supports tactical buys pre-proxy votes.

50 high priority 50 total filings
· daily

US IPO Pipeline SEC S-1 Filings — April 10, 2026

The April 10, 2026 IPO pipeline features 13 S-1 filings dominated by SPACs (Aeon, Alpex, Irenic), biotechs (Seaport, Hemab, Longeveron), and emerging growth companies, with 10 new filings signaling a surge in public market access amid biotech R&D funding needs and SPAC activity. Period-over-period trends reveal widening net losses across biotechs (Seaport +60% YoY to $74.9M, Hemab from $48.7M to $63.9M driven by R&D surges of 164% and 44% YoY respectively), offset by cash infusions from equity raises (Hemab assets doubled to $194.8M). Neutral sentiment prevails in SPACs and most others, with mixed/negative tones in biotechs due to burn rates and compliance risks; positive outliers in Irenic and HawkEye. Portfolio-level patterns include heavy R&D capital allocation in biotechs (6/13 filings), Nasdaq compliance pressures (e.g., Longeveron deadline Sept 21, 2026), and SPAC raises totaling ~$455M+ gross. Market implications point to near-term IPO catalysts but heightened dilution risks (e.g., Seaport 122M post-IPO shares) and going concern doubts, favoring selective SPAC plays over loss-making biotechs.

13 high priority 13 total filings
· daily

Global High-Priority Regulatory Events — April 10, 2026

The 50 filings reveal a bifurcated landscape: Indian companies dominate with regulatory compliance (15+ non-Large Corporate confirmations, neutral), elevated promoter encumbrances (NRB Bearings 73.91% pledged post-refinance, Camlin 77.36% of holdings), insider divestments (Delhivery holding drop 6.76% to 3.55% via 24M share sales), cyber fraud (Yash ₹2.1Cr), and ongoing insolvency (MEP 22nd CoC meeting). US/SEC filings highlight positive M&A/SPAC momentum (Constellation $500M minerals deal H2 2026 close, Willow Lane EGM Apr 30, McCormick-Unilever $600M synergies accretive Yr1), debt reductions (Hecla $263M notes redeemed fully), financings (Annovis $10M Phase 3 Alzheimer's), and board enhancements (Royale, NexMetals). Key period trend: Li Auto revenue -22.3% YoY to RMB 112B, net income -86% to RMB 1.1B, outlier underperformance vs peers. Portfolio-level patterns show Indian industrials/finance liquidity stress (4 high encumbrance cases >50% promoter holdings), US deal flow signaling growth conviction. No broad margin compression/growth trends due to event focus, but capital allocation improves via redemptions/buybacks (Riley debt -32%, $100M repurchase). Implications: Avoid Indian pledge-heavy names short-term, target US M&A catalysts for alpha.

50 high priority 50 total filings
· daily

US Earnings Financial Results SEC Filings — April 10, 2026

Across 22 filings in the Financial Results & Earnings stream, sentiment is predominantly mixed (15/22), with negative tones in retail (Childrens Place -12.8% sales YoY, FGI -1% rev), media (Cumulus -10.3% rev), and digital assets (GD Culture -96.3% cash QoQ), offset by growth outliers like Simulations Plus (+8.3% Q rev YoY, +47.5% NI) and ASP Isotopes (+475% rev). Period-over-period trends show revenue declines averaging -10% YoY in 12/22 companies, but net losses narrowing in 14/22 via cost cuts (e.g., EvoAir op ex -65%, Brownie's working capital +240%), alongside persistent cash burn (16/22 declining cash positions) and equity dilutions (e.g., Balance Labs shares +100%). Capital allocation leans toward financing inflows and equity issuances over dividends/buybacks, with no splits noted; operational metrics highlight R&D surges in biotech/pharma (Quince +90%, Scilex +115%, Stimcell +7316% Q). Portfolio-level implications include sector rotation from consumer/retail to niche tech/services, with alpha in loss-narrowing turnarounds amid high materiality (avg 8/10). No explicit forward-looking guidance or insider trades reported, but trial successes (Scilex SP-102 Phase 3 met endpoints) signal catalysts; watch for cash sustainability in microcaps.

22 high priority 22 total filings
· daily

US SEC Trading Suspension Halt Orders — April 10, 2026

A cluster of six Nasdaq-listed microcap companies received deficiency notices on April 7, 2026, primarily for failing the $1.00 minimum bid price requirement over 30 consecutive business days (Feb 23-Apr 6, 2026) or stockholders' equity below $2.5M as of Dec 31, 2025, signaling acute delisting risks across emerging growth firms. Four filings highlight bid price non-compliance, with three ineligible for standard 180-day extensions due to prior reverse stock splits (DevvStream, Beyond Air, SCWorx), while two face equity shortfalls (Caring Brands at $2.09M vs $2.5M req., Callan JMB below $2.5M). No positive period-over-period financial trends evident; persistent sub-$1 bids reflect YoY/QoQ share price deterioration amid weak fundamentals. SCWorx faces imminent trading suspension on April 14 post failed 180-day extension from 2025 notice. Portfolio implications include heightened volatility, potential OTC delistings, and liquidity evaporation for small-cap holders; no bullish insider activity or capital returns noted, all sentiments negative with high materiality (9-10/10).

6 high priority 6 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — April 10, 2026

Across 35 8-K filings in the USA Corporate Distress & Bankruptcy stream (April 10, 2026 period), distress signals dominate with 8 companies facing Nasdaq delisting risks due to sub-$1 bid prices (e.g., DevvStream, Beyond Air, SCWorx), low stockholders' equity (Caring Brands, Callan JMB), or MVLS/net income failures (Alpha Modus), reflecting microcap vulnerability amid no explicit YoY/QoQ declines but inferred weak performance from compliance breaches post-reverse splits. Countervailing trends include 12+ capital raises/ATM offerings/debt amendments (e.g., Spire Global $70M PP, Annovis $10M offering, CoreCivic revolver to $400M), signaling aggressive liquidity pursuits to avert bankruptcy. No outright bankruptcies or going-concern warnings, but lease terminations (Lyra Therapeutics $4.4M cost) and deal terminations (Dynamix SPAC) highlight cost-cutting/restructuring. Positive outliers like Hecla Mining's $263M debt redemption and Venture Global's $1.75B refinancing unlock flexibility, while mixed sentiments prevail (14/35 neutral/mixed). Portfolio-level pattern: 40% filings show financing activity vs. 23% delisting risks, with no insider trading or dividend/buyback data but forward catalysts clustered April 10-15 closings. Implications: Short-term volatility in Nasdaq microcaps; opportunities in refinancings for turnaround plays.

35 high priority 35 total filings
· daily

US Executive Officer Management Changes SEC — April 10, 2026

Across 39 filings on executive and director changes dated April 10, 2026, the dominant theme is board refreshment with 14 directors announcing non-re-election or retirement (e.g., NexMetals, Expand Energy, Cypherpunk's 4 directors), typically without disagreements, signaling proactive governance amid 2026 AGMs. Positive appointments of seasoned executives dominate in energy/mining (NexMetals' Rio Tinto vet, Royale's petroleum geologist), tech/fintech (Remitly's ex-Twitter CTO), and industrials (Caterpillar's internal CFO successor post-record $67.6B FY2025 sales), boosting sentiment in 9 cases. Retention and amended agreements (Immunic CEO bonus $670K, Longeveron RSU grants post-financing, Playboy RSUs vesting 2027-2028) highlight efforts to retain talent amid transitions, with 7 CFO/PAO changes (e.g., Expand, Kalaris, Regional Health) mostly neutral but interim leadership in smaller firms raising execution risks. No broad period-over-period deteriorations noted, but sector-specific strengths emerge like Caterpillar's YoY sales records vs. biotech churn (Vir, Immunic). Capital allocation leans toward equity incentives (PodcastOne plan doubled to 4M shares, Cherry Hill LTIP $900K target for CEO), with no dividend/buyback shifts. Overall, low materiality (avg 5.5/10) suggests limited immediate volatility, but clustered AGMs and C-suite handovers create near-term catalysts for governance scrutiny and stock reactions.

39 high priority 39 total filings
· daily

US Corporate Board Director Changes SEC Filings — April 10, 2026

Across 39 filings on USA Board Room Changes from April 10, 2026, dominant themes include board refreshment via retirements/non-re-elections (17 cases, e.g., NexMetals, Cypherpunk, Expand Energy) and new appointments of experienced executives/directors (12 cases, e.g., Remitly, Humana, Caterpillar), with neutral sentiment prevailing (70% of filings) signaling routine transitions rather than distress. Positive signals emerge in strategic hires like Remitly's ex-Twitter CTO and Caterpillar's internal CFO succession amid record $67.6B FY2025 sales, while mixed/negative notes in biotech (Immunic CEO transition, Vir Biotech CMO exit) highlight commercialization pivots. No widespread period-over-period deteriorations noted, but capital allocation trends show increased equity incentives (RSUs/options in 10 filings, e.g., PodcastOne doubling share pool to 4M, Longeveron restoring salaries + 250k-500k RSUs post-financing). Executive retention/transition packages (9 cases, e.g., Bruker $1M severance, Hawaiian Electric $200k/mo consulting) indicate stability focus amid talent wars. Portfolio-level implication: Biotech/healthcare sees highest churn (10/39, avg materiality 6.5/10), REITs emphasize comp benchmarking (Cherry Hill, Innovative Industrial), with AGMs cluster in May-June 2026 as catalysts. Overall, low disruption risk but watch for post-AGM board impacts on strategy.

39 high priority 39 total filings
· daily

US Merger & Acquisition SEC Filings — April 10, 2026

The 14 filings reveal a surge in SPAC activity with 5 new IPOs/extensions/appointments signaling renewed M&A appetite in blank-check vehicles targeting tech, private credit, and advanced materials, amid 3 director resignations and 1 delisting highlighting sector churn. Actual M&A progressed with BiomX's acquisition of Zorronet (AI defense tech) from Nukkleus, FG Merger's Boxabl deal extension to July 31, 2026, and Compass Digital's merger with Key Mining, while Ashford Hospitality's $40.5M hotel sale improved pro forma operating income 18.5% YoY to $137.9M and narrowed net loss 10.7% to $(191.8M). Jet.AI's 1-for-200 reverse split reduced shares 99.5% to maintain Nasdaq compliance, freeing shares for potential future deals. No broad insider trading activity noted, but board additions in Iron Horse, T-REX convey management conviction; sentiments skew positive/neutral (10/14) with SPAC governance tweaks dominating. Portfolio-level trends show asset sales/debt reductions enhancing balance sheets (e.g., Ashford net debt -1.6% pro forma), positioning for M&A catalysts. Distressed signals in Quetta (MVLS failure post-180 days) contrast bullish IPO momentum ($350M+ raised), implying selective opportunities in dealflow-ready SPACs vs. fading ones.

14 high priority 14 total filings
· monthly

US Pre-Market SEC Filings Roundup — April 10, 2026

Overnight SEC filings highlight a surge in proxy statements (15+ filings) signaling peak proxy season with AGMs clustered in May-June 2026, alongside active M&A/SPAC activity (McCormick-Unilever combo, Willow Lane-Boost Run, Constellation-HiTech) promising synergies and listings. Energy/mining sectors show deleveraging strength: Hecla redeemed $263M notes for unencumbered balance sheet, Riley cut debt 32% post-acquisitions with equity +22% YoY and $100M buyback. Financial results mixed: Li Auto revenues -22.3% YoY and NI -86% YoY, Qudian revenues -81.1% YoY despite NI +673% on non-op income, contrasting Welltower's 14.1% YoY NOI growth and 228.2% cumulative TSR 2021-2025. Capital allocation favors shareholders with dividend hikes (Riley +5%, Welltower +10.4%) and buybacks (News Corp $1B program, Riley $100M). No widespread insider selling patterns, but board refreshers indicate governance focus; forward catalysts include earnings previews and de-SPAC closings H2 2026. Portfolio trend: Positive sentiment dominates (25+ bullish/neutral), with outliers in China-exposed autos/fintech dragging, implying overweight energy/REITs ahead of catalysts.

27 high priority 23 medium 50 total filings